Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amarin Corporation plc - American Depositary Shares (NQ:AMRN)

12.13 -0.22 (-1.78%)
Delayed Quote Updated: 1:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amarin Corporation plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Amarin Appoints Patrick Holt as President and Chief Executive Officer
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Morgan Stanley, Charles Schwab, Bank of America, And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded mostly higher, with the Dow Jones gaining over 200 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Amarin Corp's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Amarin Plc (AMRN) Q1 2023 Earnings Call Transcript ↗
AMRN earnings call for the period ending March 31, 2023. 
Via The Motley Fool
News headline image
Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA)
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Present at Two Upcoming Investor Conferences
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China
From Amarin Corporation plc
Via GlobeNewswire
News headline image
3 Biotech Stocks to Avoid Like the Plague ↗
Investors are looking for bargains in the biotech sector. But these three biotech stocks should be avoided at all costs. 
Via InvestorPlace
News headline image
Recap: Amarin Corp Q1 Earnings ↗
 
Via Benzinga
News headline image
Amarin Plc (AMRN) Q4 2022 Earnings Call Transcript ↗
AMRN earnings call for the period ending December 31, 2022. 
Via The Motley Fool
News headline image
Earnings Scheduled For March 1, 2023 ↗
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
News headline image
Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Reports Stable Revenue, Cash Position In Q1 But Lowers FY23 Operating Expense Guidance: What's Next? ↗
 
Via Benzinga
News headline image
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Why Agenus, Amarin, and Axsome Therapeutics Shares Slumped Today ↗
Macro headwinds are weighing on risk-laden biotech stocks today. 
Via The Motley Fool
News headline image
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Announces Board Departures
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome ↗
 
Via Benzinga
News headline image
Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Sarissa Capital Wins Proxy Contest Against Amarin by Huge Landslide
From Sarissa Capital Management LP
Via Business Wire
News headline image
Amarin Announces Preliminary Voting Results Following 2023 General Meeting of Shareholders
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Sets the Record Straight on Sarissa’s Latest Misstatements
From Amarin Corporation plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.